Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caffeine Citrate in Preterm Infants at Risk of Apnea
NCT06518603Phase 4Recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Jun 2026
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in apnea of prematurity (AOP) comparing Oral Caffeine Citrate 20mg/kg/day with Placebo (2 arms). Primary endpoints: Number of apneic events at 28 days and Number of visits to healthcare professionals related to apneic events at 28 days. Started Jun 2026; status: recruiting.
02
Drugs
caffeine
03
Conditions
apnea of prematurity (AOP)
Beyond the preview
Go deeper on NCT06518603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06518603.